Daiichi Suntory Pharma Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: George Nakayama), one of the group companies of Daiichi Pharmaceutical Co., Ltd., and Replidyne, Inc. (Headquarters: Louisville, Colorado; President & CEO: Kenneth J. Collins) today announced they have entered into a license agreement for a penem-type antibiotic agent known as faropenem daloxate.
Replidyne has acquired exclusive rights to develop, manufacture and market this agent in the North American countries, USA and Canada . Replidyne plans to start phase III trials for this agent in the U.S. within this year.
Reference: Faropenem daloxate is a prodrug of Faropenem sodium, the first oral penem-type antibiotic launched in 1997 in Japan (marketed by Yamanouchi Pharmaceutical Co., Ltd. with trade name Farom). It is orally active and well absorbed through the gastro-intestinal tract, and transformed into Faropenem. It is effective against various infections, including the problematic antibiotic-resistant bacteria, PRSP (penicillin-resistant Streptococcus pneumoniae).
Daiichi Suntory Pharma Co., Ltd.
| Head Office: |
5-7-2 Kojimachi, Chiyoda-ku, Tokyo , JAPAN |
| President: |
George Nakayama |
| Date of Establishment: |
December 27, 2002 |
| Capital: |
¥1 billion |
| Stockholders: |
Daiichi Pharmaceutical Co., Ltd. 66%, Suntory Ltd. 34% |
| Employees (as a group): |
340 (as of December 31, 2003 ) |
| Primary Business: |
Research and development, manufacture, and sales of pharmaceuticals |
|
Replidyne,Inc.
| Head Office: |
1450 Infinite Drive , Louisville , CO 80027 U.S.A. |
| President: |
Kenneth J. Collins |
| Date of Establishment: |
January 2000 |
| Stockholders: |
Healthcare Ventures, etc. |
| Employees: |
36人 36 (as of December 31, 2003 ) |
| Primary Business: |
Research and development of pharmaceuticals |
|
|
